Progyny › Financials
Ten years from Progyny’s own SEC filings. Fiscal years end in December.
| Dec 2017fiscal year | Dec 2018fiscal year | Dec 2019fiscal year | Dec 2020fiscal year | Dec 2021fiscal year | Dec 2022fiscal year | Dec 2023fiscal year | Dec 2024fiscal year | Dec 2025fiscal year | Last 12 monthsto Jun 2026 | Latest quarterJun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $48.6M | $105.4M | $229.7M | $344.9M | $500.6M | $786.9M | $1.09B | $1.17B | $1.29B | $1.31B | — |
| Gross profit | $7.4M | $19.4M | $45.5M | $70.1M | $112.1M | $167.3M | $238.8M | $253.4M | $304.5M | $322.1M | — |
| Operating income | −$11.0M | −$3.5M | $9.7M | $8.3M | $32.3M | $23.3M | $62.2M | $67.5M | $85.3M | $112.1M | — |
| Net income | −$12.5M | $661K | −$8.6M | $46.5M | $65.8M | $30.4M | $62.0M | $54.3M | $58.5M | $78.6M | — |
| Earnings per share, diluted | −$2.37 | $0.04 | −$0.41 | $0.47 | $0.66 | $0.30 | $0.62 | $0.57 | $0.65 | — | — |
| Dec 2017fiscal year | Dec 2018fiscal year | Dec 2019fiscal year | Dec 2020fiscal year | Dec 2021fiscal year | Dec 2022fiscal year | Dec 2023fiscal year | Dec 2024fiscal year | Dec 2025fiscal year | Last 12 monthsto Jun 2026 | Latest quarterJun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | — | $127K | $80.4M | $70.3M | $91.4M | $120.1M | $97.3M | $162.3M | $112.2M | — | $152.6M |
| Total assets | — | $41.3M | $150.4M | $253.9M | $358.1M | $543.0M | $756.6M | $607.1M | $742.4M | — | $715.8M |
| Total liabilities | — | $30.2M | $36.2M | $87.0M | $106.2M | $166.0M | $203.2M | $185.0M | $226.4M | — | $262.6M |
| Shareholders' equity | −$97.6M | −$95.1M | $114.3M | $166.9M | $251.8M | $377.0M | $553.4M | $422.1M | $516.0M | — | $453.3M |
| Dec 2017fiscal year | Dec 2018fiscal year | Dec 2019fiscal year | Dec 2020fiscal year | Dec 2021fiscal year | Dec 2022fiscal year | Dec 2023fiscal year | Dec 2024fiscal year | Dec 2025fiscal year | Last 12 monthsto Jun 2026 | Latest quarterJun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | −$9.5M | $2.3M | −$1.5M | $36.2M | $26.0M | $80.4M | $188.8M | $179.1M | $210.2M | $201.2M | — |
| Capital spending | $612K | $579K | $3.0M | $1.0M | $2.1M | $3.2M | $3.6M | $5.4M | $18.4M | $22.9M | — |
| Free cash flow | −$10.1M | $1.7M | −$4.5M | $35.2M | $23.9M | $77.2M | $185.2M | $173.7M | $191.8M | $178.4M | — |
| Buybacks | — | $1.2M | $185K | — | — | $0 | $0 | $300.3M | $81.7M | $230.3M | — |
| Returned to shareholders | — | $1.2M | $185K | — | — | $0 | $0 | $300.3M | $81.7M | $230.3M | — |
| Stock-based pay | $1.6M | $3.0M | $5.1M | $12.8M | $33.7M | $100.7M | $122.6M | $128.1M | $131.9M | $107.2M | — |
Every column links to the filing it comes from on EDGAR. Last 12 months adds the latest year to date to the last 10-K and takes away the same months a year earlier. Debt is long-term debt including the part due within a year. A dash means the company did not report that line in a form we can read, never a zero. Market cap uses the latest closing price and the share count from the cover of the latest filing. How we count
$2.06B at $26.86 a share, with 76,726,798 shares outstanding as of Jul 31, 2026, from the cover of its latest SEC filing.
Revenue of $1.31B and net income of $78.6M in the last 12 months to Jun 2026.
Progyny reported $152.6M of cash and equivalents on its balance sheet in Jun 2026.
Yes. Operating cash flow minus capital spending was $178.4M in the last 12 months to Jun 2026.
$81.7M in buybacks and dividends in fiscal 2025, from the cash flow statement.
Free. Your email goes to Substack, which runs the newsletter. Privacy